Update on the Therapeutic Drug Monitoring in IBD: Is it Time We Use it in Situations other Than Loss of Response

08/06/2018

Related Content

Cardiometabolic Risk
Margo B. Minissian and Edward Shahady
Cardiometabolic Risk
CRS 2016: Cardiometabolic Risk and Related Comorbidities, Part 2
10/14/2016
Co-Chairs from the 2016 Cardiometabolic Risk Summit, Margo B. Minissian, PhDc, ACNP, CLS, AACC, FAHA and Edward Shahady, MD, FAAFP, ABCL,  discuss details from the panel discussions which take...
10/14/2016
Cardiometabolic Risk
Cardiometabolic Risk
William E. Boden, MD, on A New Risk Score for Mortality and Myocardial Infarction in Patients With Stable Coronary Artery Disease: The COURAGE Risk Prediction Tool
08/10/2020
In this video, William Boden, MD, explains how the COURAGE Risk Prediction Tool works and what its impact can be on treatment optimization.
08/10/2020
Rheumatology
Rheumatology
Karen Onel, MD, on Why the New JIA Guideline Is Needed
01/06/2021
In this video, Karen Onel, MD, explains why the most recent JIA recommendations are needed as well as what new areas they address that had not been included in past guidelines.
01/06/2021
Gastroenterology
Gastroenterology
Choosing and Optimizing Therapy Today While Preparing for Tomorrow
08/06/2018
08/06/2018
Gastroenterology
video
Gastroenterology
What are the risks of malignancies due to having IBD and being on immunomodulators and/or biologics: How can we help our patients avoid those risks?
08/07/2018
08/07/2018